Top of page

PROACT: A phase 3 trial testing whether a drug called enalapril can prevent heart damage linked to chemotherapy in people with lymphoma or breast cancer

This phase three trial is testing whether enalapril can reduce cardiotoxicity in people with non-Hodgkin lymphoma who are due to start chemotherapy treatment with CHOP or R-CHOP. The trial is also being run in people with breast cancer.


Trial aim and background

The aim of this trial is to find out whether a drug called enalapril can prevent heart damage linked to certain chemotherapy regimens in people who have non-Hodgkin lymphoma or breast cancer.

Enalapril is a type of drug called an ‘angiotensin-converting enzyme (ACE) inhibitor’. It is usually used to treat high blood pressure or heart failure. This trial is testing whether it can prevent the heart damage that can be caused by chemotherapy.

Everybody who takes part in the PROACT trial is treated with their planned course of chemotherapy (on its own or with rituximab). Half of the people who take part will be randomly allocated to the treatment group who will also be treated with enalapril. The other half, the control group, will just receive the chemotherapy, which is currently how people are treated

The enalapril is taken as a tablet take twice a day, starting just before the first course of chemotherapy and finishing 3 weeks after the last course. Damage to the heart is established with blood tests and a heart scan (echocardiogram).


Who can enter

Anyone over 18 with non-Hodgkin lymphoma who is due to be treated with CHOP or R-CHOP may be eligible to enter this trial.


Locations

Recruitment is taking place at South Tees Hospital, Middlesbrough. 


Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://beta.clinicaltrials.gov/study/NCT03265574

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.